<article title='Anxiolytic'><paragraph><template><target>Refimprove</target><arg name="date">September 2015</arg></template><template><target>Medref</target><arg name="date">September 2015</arg></template><template><target>Use dmy dates</target><arg name="date">July 2013</arg></template>An<space/><bold>anxiolytic</bold><space/>(also<space/><bold>antipanic</bold><space/>or<space/><bold>antianxiety agent</bold>)<extension extension_name='ref'><template><target>DorlandsDict</target><arg>nine/100020674</arg><arg>antianxiety agent</arg></template></extension><space/>is a medication or other intervention that inhibits<space/><link><target>anxiety</target></link>. This effect is in contrast to<space/><link><target>anxiogenic</target></link><space/>agents, which increase anxiety. Together these categories of<space/><link><target>Psychoactive drug</target><part>psychoactive</part></link><space/>compounds or interventions may be referred to as<space/><link><target>anxiotropic</target></link><space/>compounds/agents. Some<space/><link><target>Recreational drug use</target><part>recreational drugs</part></link><space/>such as<space/><link><target>ethanol</target></link><space/>(<link><target>ethanol</target><part>alcohol</part></link>) induce anxiolysis initially, however studies show that many of these drugs are anxiogenic. Anxiolytic<space/><link><target>medication</target><trail>s</trail></link><space/>have been used for the treatment of<space/><link><target>anxiety</target></link><space/>and its related psychological and physical symptoms. Anxiolytics have been shown to be useful in the treatment of<space/><link><target>anxiety disorder</target><trail>s</trail></link>.<space/><link><target>Light therapy</target></link><space/>and other interventions have also been found to have an anxiolytic effect.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1186/1471-244X-7-62<space/></arg><arg name="title">Does bright light have an anxiolytic effect? - an open trial<space/></arg><arg name="year">2007<space/></arg><arg name="last1">Youngstedt<space/></arg><arg name="first1">Shawn D<space/></arg><arg name="last2">Kripke<space/></arg><arg name="first2">Daniel F<space/></arg><arg name="journal">BMC Psychiatry<space/></arg><arg name="volume">7<space/></arg><arg name="pages">62<space/></arg><arg name="pmid">17971237<space/></arg><arg name="pmc">2194679</arg></template></extension></paragraph><paragraph><link><target>Beta-receptor blocker</target><trail>s</trail></link><space/>such as<space/><link><target>propranolol</target></link><space/>and<space/><link><target>oxprenolol</target></link>, although not anxiolytics, can be used to combat the<space/><link><target>Somatopsychic</target><part>somatic</part></link><space/>symptoms of anxiety, as<space/><link><target>tachycardia</target></link><space/>and<space/><link><target>palpitation</target><trail>s</trail></link>.<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Beta-blockers in anxiety disorders<space/></arg><arg name="author">Peggy E. Hayes<space/></arg><arg name="journal">Journal of Affective Disorders</arg><arg name="volume">13<space/></arg><arg name="issue">2<space/></arg><arg name="date">September–October 1987<space/></arg><arg name="pages">119–130<space/></arg><arg name="url">http://www.sciencedirect.com/science/article/pii/0165032787900176</arg><arg name="display-authors">etal</arg></template></extension></paragraph><paragraph>Anxiolytics are also known as<space/><bold>minor<space/><link><target>tranquilizer</target><trail>s</trail></link></bold>.<extension extension_name='ref'><template><target>cite web</target><arg name="url">http://www.memidex.com/anxiolytic+tranquilizer</arg><arg name="title">anxiolytic (tranquilizer)</arg><arg name="work">Memidex (WordNet) Dictionary/Thesaurus<space/></arg><arg name="accessdate">2010-12-02</arg></template></extension><space/>The term is less common in modern texts, and was originally derived from a dichotomy with<space/><link><target>major tranquilizer</target><trail>s</trail></link>, also known as<space/><link><target>neuroleptics</target></link><space/>or<space/><link><target>antipsychotics</target></link>.<template><target>citation needed</target><arg name="date">January 2011</arg></template></paragraph><heading level='2'>Alternatives to medication</heading><paragraph>Psychotherapeutic treatment can be an effective alternative to medication.<extension extension_name='ref' name="Zwanzger-2007"><template><target>Cite journal</target><arg name="last1"><space/>Zwanzger<space/></arg><arg name="first1"><space/>P.<space/></arg><arg name="last2"><space/>Deckert<space/></arg><arg name="first2"><space/>J.<space/></arg><arg name="title"><space/>[Anxiety disorders. Causes, clinical picture and treatment]<space/></arg><arg name="journal"><space/>Nervenarzt<space/></arg><arg name="volume"><space/>78<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>349–59; quiz 360<space/></arg><arg name="date">Mar 2007<space/></arg><arg name="doi"><space/>10.1007/s00115-006-2202-z<space/></arg><arg name="pmid"><space/>17279399<space/></arg></template></extension><space/><link><target>Exposure therapy</target></link><space/>is the recommended treatment for phobic anxiety disorders.<space/><link><target>Cognitive behavioral therapy</target></link><space/>(CBT) has been found to be effective treatment for<space/><link><target>panic disorder</target></link>,<space/><link><target>social anxiety disorder</target></link>,<space/><link><target>generalized anxiety disorder</target></link>, and<space/><link><target>obsessive-compulsive disorder</target></link>. Healthcare providers can also help by educating sufferers about anxiety disorders and referring individuals to self-help resources.<extension extension_name='ref' name="Shearer-2007"><template><target>Cite journal</target><arg name="last1"><space/>Shearer<space/></arg><arg name="first1"><space/>SL.<space/></arg><arg name="title"><space/>Recent advances in the understanding and treatment of anxiety disorders<space/></arg><arg name="journal"><space/>Prim Care<space/></arg><arg name="volume"><space/>34<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>475–504, v–vi<space/></arg><arg name="date">Sep 2007<space/></arg><arg name="doi"><space/>10.1016/j.pop.2007.05.002<space/></arg><arg name="pmid"><space/>17868756<space/></arg></template></extension><space/>CBT has been shown to be effective in the treatment of<space/><link><target>generalized anxiety disorder</target></link>, and possibly more effective than pharmacological treatments in the long term.<extension extension_name='ref'><template><target>Cite journal</target><arg name="doi"><space/>10.1016/S0005-7894(97)80048-2<space/></arg><arg name="volume"><space/>28<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>285–305<space/></arg><arg name="last"><space/>Gould<space/></arg><arg name="first"><space/>RA<space/></arg><arg name="title"><space/>Cognitive behavioral and pharmacological treatment of generalized anxiety disorder: A preliminary meta-analysis<space/></arg><arg name="journal"><space/>Behavior Therapy<space/></arg><arg name="year"><space/>1997<space/></arg><arg name="last2"><space/>Otto<space/></arg><arg name="first2"><space/>M<space/></arg><arg name="last3"><space/>Pollack<space/></arg><arg name="first3"><space/>M<space/></arg><arg name="last4"><space/>Yap<space/></arg><arg name="first4"><space/>L<space/></arg></template></extension><space/>Sometimes medication is combined with psychotherapy, but research has not found a benefit of combined pharmacotherapy and psychotherapy versus monotherapy.<extension extension_name='ref' name="Pull-2007"><template><target>Cite journal</target><arg name="last1"><space/>Pull<space/></arg><arg name="first1"><space/>CB.<space/></arg><arg name="title"><space/>Combined pharmacotherapy and cognitive-behavioural therapy for anxiety disorders<space/></arg><arg name="journal"><space/>Curr Opin Psychiatry<space/></arg><arg name="volume"><space/>20<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>30–5<space/></arg><arg name="date">Jan 2007<space/></arg><arg name="doi"><space/>10.1097/YCO.0b013e3280115e52<space/></arg><arg name="pmid"><space/>17143079<space/></arg></template></extension></paragraph><paragraph>However, even with CBT being a viable treatment option, it can still be ineffective for many individuals. Both the Canadian and American medical associations then suggest the use of a strong but long lasting benzodiazepine such as<space/><link><target>clonazepam</target></link><space/>and<space/><link><target>alprazolam</target></link><space/>and an antidepressant, usually<space/><link><target>Prozac</target></link><space/>for its effectiveness.<extension extension_name='ref'>CMA &amp; AMA Home medical guides 2012 &amp; 2014, along with personal experiences and WebMD reviews</extension><template><target>Unreliable source?</target><arg name="certain">y</arg><arg name="reason">Self-explanatory</arg><arg name="date">September 2015</arg></template><template><target>OR</target><arg name="date">September 2015</arg></template></paragraph><paragraph>Note that adolescent anxiety once the patient becomes pubescent can often turn into depression, at which time other treatments may be required.<template><target>citation needed</target><arg name="reason">Source?</arg><arg name="date">September 2015</arg></template></paragraph><heading level='2'>Medications</heading><heading level='3'>Barbiturates</heading><paragraph><template><target>Main</target><arg>Barbiturate</arg></template></paragraph><paragraph><link><target>Barbiturate</target><trail>s</trail></link><space/>exert an anxiolytic effect linked to the sedation they cause. The risk of abuse and addiction is high. Many experts consider these drugs obsolete for treating anxiety but valuable for the short-term treatment of severe insomnia, though only after benzodiazepines or non-benzodiazepines have failed.</paragraph><heading level='3'>Benzodiazepines</heading><paragraph><template><target>Main</target><arg>Benzodiazepine</arg></template></paragraph><paragraph>Benzodiazepines are prescribed for short-term relief of severe and disabling anxiety. Benzodiazepines may also be indicated to cover the latent periods associated with the medications prescribed to treat an underlying anxiety disorder. They are used to treat a wide variety of conditions and symptoms and are usually a first choice when short-term<space/><link><target>Central nervous system</target><part>CNS</part></link><space/><link><target>sedation</target></link><space/>is needed. Longer-term uses include treatment for severe anxiety. If benzodiazepines are discontinued rapidly after being taken daily for two or more weeks there is a risk of<space/><link><target>benzodiazepine withdrawal</target></link><space/>and<space/><link><target>rebound syndrome</target></link>, and tolerance and dependence may also occur, but may be clinically acceptable.<extension extension_name='ref'>Gelder, M, Mayou, R. and Geddes, J. 2005. Psychiatry. 3rd ed. New York: Oxford. pp236.</extension><space/>There is also the added problem of the accumulation of drug<space/><link><target>metabolite</target><trail>s</trail></link><space/>and adverse effects.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Lader M, Tylee A, Donoghue J<space/></arg><arg name="title">Withdrawing benzodiazepines in primary care<space/></arg><arg name="journal">CNS Drugs<space/></arg><arg name="volume">23<space/></arg><arg name="issue">1<space/></arg><arg name="pages">19–34<space/></arg><arg name="year">2009<space/></arg><arg name="pmid">19062773<space/></arg><arg name="doi">10.2165/0023210-200923010-00002<space/></arg><arg name="url"></arg></template></extension><space/>Benzodiazepines include:</paragraph><list type='bullet'><listitem><link><target>Alprazolam</target></link><space/>(Xanax)</listitem><listitem><link><target>Bromazepam</target></link><space/>(Lectopam, Lexotan)</listitem><listitem><link><target>Chlordiazepoxide</target></link><space/>(Librium)</listitem><listitem><link><target>Clonazepam</target></link><space/>(Klonopin, Rivotril)</listitem><listitem><link><target>Clorazepate</target></link><space/>(Tranxene)</listitem><listitem><link><target>Diazepam</target></link><space/>(Valium)</listitem><listitem><link><target>Flurazepam</target></link><space/>(Dalmane)</listitem><listitem><link><target>Lorazepam</target></link><space/>(Ativan)</listitem><listitem><link><target>Oxazepam</target></link><space/>(Serax, Serapax)</listitem><listitem><link><target>Temazepam</target></link><space/>(Restoril)</listitem><listitem><link><target>Triazolam</target></link><space/>(Halcion)</listitem></list><paragraph>Benzodiazepines exert their anxiolytic properties at moderate dosage. At higher dosage<space/><link><target>hypnotic</target></link><space/>properties occur.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1590/S0004-282X2005000300009<space/></arg><arg name="title">Neuromodulatory effects of caffeine and bromazepam on visual event-related potential (P300): A comparative study<space/></arg><arg name="year">2005<space/></arg><arg name="last1">Montenegro<space/></arg><arg name="first1">Mariana<space/></arg><arg name="last2">Veiga<space/></arg><arg name="first2">Heloisa<space/></arg><arg name="last3">Deslandes<space/></arg><arg name="first3">Andréa<space/></arg><arg name="last4">Cagy<space/></arg><arg name="first4">Maurício<space/></arg><arg name="last5">McDowell<space/></arg><arg name="first5">Kaleb<space/></arg><arg name="last6">Pompeu<space/></arg><arg name="first6">Fernando<space/></arg><arg name="last7">Piedade<space/></arg><arg name="first7">Roberto<space/></arg><arg name="last8">Ribeiro<space/></arg><arg name="first8">Pedro<space/></arg><arg name="journal">Arquivos de Neuro-Psiquiatria<space/></arg><arg name="volume">63<space/></arg><arg name="issue">2b<space/></arg><arg name="pages">410–5<space/></arg><arg name="pmid">16059590</arg></template></extension></paragraph><list type='bullet'><listitem><link><target>Tofisopam</target></link><space/>(Emandaxin and Grandaxin) is a drug that is a benzodiazepine derivative. Like other benzodiazepines, it possesses anxiolytic properties, but, unlike other benzodiazepines, it does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing, or amnestic properties.</listitem></list><heading level='3'>Antidepressants</heading><heading level='4'>Serotonergic antidepressants</heading><paragraph><link><target>Selective serotonin reuptake inhibitors</target></link><space/>or<space/><bold>serotonin-specific reuptake inhibitor</bold><extension extension_name='ref' name="BARLOW"><template><target>cite book</target><arg name="author">Barlow, David H. Durand, V. Mark<space/></arg><arg name="title">Abnormal Psychology: An Integrative Approach<space/></arg><arg name="edition">Fifth<space/></arg><arg name="page">239<space/></arg><arg name="chapter">Chapter 7: Mood Disorders and Suicide<space/></arg><arg name="isbn">0-495-09556-7<space/></arg><arg name="oclc">192055408<space/></arg><arg name="location">Belmont, CA<space/></arg><arg name="publisher">Wadsworth Cengage Learning<space/></arg><arg name="year">2009</arg></template></extension><space/>(<bold>SSRIs</bold>) are a class of compounds typically used as<space/><link><target>antidepressant</target><trail>s</trail></link><space/>in the treatment of<space/><link><target>Major depressive disorder</target><part>depression</part></link>,<space/><link><target>anxiety disorder</target><trail>s</trail></link>, and some<space/><link><target>personality disorder</target><trail>s</trail></link>. SSRIs are primarily classified as antidepressants and typically higher dosages are required to be effective against<space/><link><target>anxiety disorders</target></link><space/>than to be effective against depression; nevertheless, most SSRIs have anxiolytic properties. They can, however, be<space/><link><target>anxiogenic</target></link><space/>early on in the course of treatment due to negative feedback through the serotonergic<space/><link><target>autoreceptors</target></link>. For this reason in some individuals a low dose concurrent benzodiazepine therapy might be beneficial during the early stages of serotonergic therapy to counteract the initial anxiogenic effects current serotonergics antidepressants have.</paragraph><heading level='4'>Serotoninnorepinephrine reuptake inhibitor</heading><paragraph><link><target>Serotoninnorepinephrine reuptake inhibitor</target></link><space/>include<space/><link><target>venlafaxine</target></link><space/>and<space/><link><target>duloxetine</target></link><space/>drugs. Venlafaxine, in<space/><link><target>extended release</target></link><space/>form, and duloxetine, are indicated for the treatment of<space/><link><target>Generalized anxiety disorder</target><part>GAD</part></link>. SSNRIs are as effective as SSRIs in the treatment of anxiety disorders.<extension extension_name='ref' name="Vanin"><template><target>cite book</target><arg name="title">Anxiety Disorders: A Pocket Guide For Primary Care<space/></arg><arg name="author">John Vanin, James Helsley<space/></arg><arg name="publisher">Springer Science & Business Media<space/></arg><arg name="date">19 June 2008<space/></arg><arg name="page">189</arg></template></extension></paragraph><heading level='4'>Tricyclic antidepressant</heading><paragraph>Older<space/><link><target>tricyclic antidepressants</target></link><space/>(TCAs) are anxiolytic too; however, their side effects are often more severe in nature. Examples include<space/><link><target>imipramine</target></link>,<space/><link><target>doxepin</target></link>,<space/><link><target>amitriptyline</target></link>, and the unrelated<space/><link><target>trazodone</target></link>.<template><target>mcn</target><arg name="date">October 2015</arg></template></paragraph><heading level='4'>Tetracyclic antidepressant</heading><paragraph><link><target>Mirtazapine</target></link><space/>has demonstrated anxiolytic effects with a better side effect profile to all other classes of antidepressants, for example it rarely causes or exacerbates anxiety. However, it in many countries (such as USA and Australia) it is not specifically approved for anxiety disorders and is only used off label.</paragraph><heading level='4'>Monoamine oxidase inhibitors</heading><paragraph><link><target>Monoamine oxidase inhibitors</target></link><space/>(MAOIs) are very effective for anxiety, but due to drug dangers, are rarely prescribed. Examples include:<space/><link><target>phenelzine</target></link><space/>and<space/><link><target>tranylcypromine</target></link>. A reversible MAOI, which has none of the dietary restrictions associated with classic MAOI's,<space/><link><target>moclobemide</target></link><space/>is used in Canada and the UK as Manerix and in Australia as Aurorix which have none of the more severe<space/><link><target>SSRI</target></link>'s and<space/><link><target>SNRI</target></link>'s caused<space/><link><target>SSRI discontinuation syndrome</target></link>, an often overlooked and damaging syndrome which is objectively and subjectively as bad or, for some, even worse than<space/><link><target>Benzodiazepine withdrawal syndrome</target></link>.<template><target>mcn</target><arg name="date">October 2015</arg></template></paragraph><heading level='3'>Beta blockers</heading><paragraph>Although not officially approved for this purpose,<space/><link><target>Beta blocker</target><trail>s</trail></link><space/>also can have an antianxiety effect.<extension extension_name='ref'>Jefferson, J. W. (1974). Beta-adrenergic receptor blocking drugs in psychiatry. Archives of general psychiatry, 31(5), 681. doi:10.1001/archpsyc.1974.01760170071012 http://archpsyc.jamanetwork.com/article.aspx?articleid=491265</extension><extension extension_name='ref'>Noyes Jr, R. (1982). Beta-blocking drugs and anxiety. Psychosomatics, 23(2), 155-170.</extension></paragraph><heading level='3'>Miscellaneous</heading><heading level='4'>Alpha-adrenergic agonist</heading><paragraph>Alpha 2A receptor agonists<space/><link><target>Clonidine</target></link><space/>and<space/><link><target>Guanfacine</target></link><space/>has demonstrated both anxiolytic and anxiogenic effects.</paragraph><heading level='4'>Mebicar</heading><paragraph><link><target>Mebicar</target></link><space/>(mebicarum) is an anxiolytic produced in<space/><link><target>Latvia</target></link><space/>and used in Eastern Europe. Mebicar has an effect on the structure of limbic-reticular activity, particularly on<space/><link><target>hypothalamus</target></link><space/>emotional zone, as well as on all 4 basic neuromediator systems<space/><link><target>gamma-aminobutyric acid</target><part>aminobutyric acid</part></link><space/>(GABA),<space/><link><target>choline</target></link>,<space/><link><target>serotonin</target></link><space/>and adrenergic activity.<extension extension_name='ref'><template><target>cite web</target><arg name="title">Adaptol. Summary of Product Characteristics<space/></arg><arg name="url">http://olainfarm.lv/wp-content/uploads/2013/01/ADAPTOL_Summary-of-Product-Characteristics.pdf<space/></arg><arg name="access-date">24 July 2015</arg></template></extension><space/>Mebicar decreases the brain noradrenaline level, exerts no effect on the dopaminergic systems, and increases the brain serotonin level.<extension extension_name='ref' name="Missingor"><template><target>cite journal</target><arg name="pmid">6104993<space/></arg><arg name="year">1980<space/></arg><arg name="last1">Val'Dman<space/></arg><arg name="first1">AV<space/></arg><arg name="last2">Zaikonnikova<space/></arg><arg name="first2">IV<space/></arg><arg name="last3">Kozlovskaia<space/></arg><arg name="first3">MM<space/></arg><arg name="last4">Zimakova<space/></arg><arg name="first4">IE<space/></arg><arg name="title">Characteristics of the psychotropic spectrum of action of mebicar<space/></arg><arg name="volume">89<space/></arg><arg name="issue">5<space/></arg><arg name="pages">568–70<space/></arg><arg name="journal">Biulleten' eksperimental'noi biologii i meditsiny</arg></template></extension></paragraph><heading level='4'>Fabomotizole</heading><paragraph><link><target>Fabomotizole</target></link><extension extension_name='ref'><template><target>cite journal</target><arg name="title">International Nonproprietary Names for Pharmaceutical Substances (INN)</arg><arg name="journal">WHO Drug Information</arg><arg name="date">2012</arg><arg name="volume">26</arg><arg name="issue">1</arg><arg name="page">63</arg><arg name="url">http://www.who.int/medicines/publications/druginformation/issues/RL67.pdf</arg><arg name="accessdate">21 March 2015</arg></template></extension><space/>(brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. Its mechanism of action remains poorly defined, with GABAergic, NGF and BDNF release promoting, MT1 receptor antagonism, MT3 receptor antagonism, and sigma agonism all thought to have some involvement.<extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Neznamov<space/></arg><arg name="first1"><space/>GG<space/></arg><arg name="last2"><space/>Siuniakov<space/></arg><arg name="first2"><space/>SA<space/></arg><arg name="last3"><space/>Chumakov<space/></arg><arg name="first3"><space/>DV<space/></arg><arg name="last4"><space/>Bochkarev<space/></arg><arg name="first4"><space/>VK<space/></arg><arg name="last5"><space/>Seredenin<space/></arg><arg name="first5"><space/>SB<space/></arg><arg name="title"><space/>Clinical study of the selective anxiolytic agent afobazol<space/></arg><arg name="journal"><space/>Eksperimental'naia i klinicheskaia farmakologiia<space/></arg><arg name="volume"><space/>64<space/></arg><arg name="issue"><space/>2<space/></arg><arg name="pages"><space/>15–9<space/></arg><arg name="year"><space/>2001<space/></arg><arg name="pmid"><space/>11548440<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Silkina<space/></arg><arg name="first1"><space/>IV<space/></arg><arg name="last2"><space/>Gan'shina<space/></arg><arg name="first2"><space/>TC<space/></arg><arg name="last3"><space/>Seredin<space/></arg><arg name="first3"><space/>SB<space/></arg><arg name="last4"><space/>Mirzoian<space/></arg><arg name="first4"><space/>RS<space/></arg><arg name="title"><space/>Gabaergic mechanism of cerebrovascular and neuroprotective effects of afobazole and picamilon<space/></arg><arg name="journal"><space/>Eksperimental'naia i klinicheskaia farmakologiia<space/></arg><arg name="volume"><space/>68<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>20–4<space/></arg><arg name="year"><space/>2005<space/></arg><arg name="pmid"><space/>15786959<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Seredin<space/></arg><arg name="first1"><space/>SB<space/></arg><arg name="last2"><space/>Melkumian<space/></arg><arg name="first2"><space/>DS<space/></arg><arg name="last3"><space/>Val'dman<space/></arg><arg name="first3"><space/>EA<space/></arg><arg name="last4"><space/>Iarkova<space/></arg><arg name="first4"><space/>MA<space/></arg><arg name="last5"><space/>Seredina<space/></arg><arg name="first5"><space/>TC<space/></arg><arg name="last6"><space/>Voronin<space/></arg><arg name="first6"><space/>MV<space/></arg><arg name="last7"><space/>Lapitskaia<space/></arg><arg name="first7"><space/>AS<space/></arg><arg name="title"><space/>Effects of afobazole on the BDNF content in brain structures of inbred mice with different phenotypes of emotional stress reaction<space/></arg><arg name="journal"><space/>Eksperimental'naia i klinicheskaia farmakologiia<space/></arg><arg name="volume"><space/>69<space/></arg><arg name="issue"><space/>3<space/></arg><arg name="pages"><space/>3–6<space/></arg><arg name="year"><space/>2006<space/></arg><arg name="pmid"><space/>16878488<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Antipova<space/></arg><arg name="first1"><space/>TA<space/></arg><arg name="last2"><space/>Sapozhnikova<space/></arg><arg name="first2"><space/>DS<space/></arg><arg name="last3"><space/>Bakhtina<space/></arg><arg name="first3"><space/>LIu<space/></arg><arg name="last4"><space/>Seredenin<space/></arg><arg name="first4"><space/>SB<space/></arg><arg name="title"><space/>Selective anxiolytic afobazole increases the content of BDNF and NGF in cultured hippocampal HT-22 line neurons<space/></arg><arg name="journal"><space/>Eksperimental'naia i klinicheskaia farmakologiia<space/></arg><arg name="volume"><space/>72<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>12–4<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19334503<space/></arg></template></extension><extension extension_name='ref'><template><target>cite journal</target><arg name="last1"><space/>Seredenin<space/></arg><arg name="first1"><space/>SB<space/></arg><arg name="last2"><space/>Antipova<space/></arg><arg name="first2"><space/>TA<space/></arg><arg name="last3"><space/>Voronin<space/></arg><arg name="first3"><space/>MV<space/></arg><arg name="last4"><space/>Kurchashova<space/></arg><arg name="first4"><space/>SY<space/></arg><arg name="last5"><space/>Kuimov<space/></arg><arg name="first5"><space/>AN<space/></arg><arg name="title"><space/>Interaction of afobazole with sigma1-receptors<space/></arg><arg name="journal"><space/>Bulletin of experimental biology and medicine<space/></arg><arg name="volume"><space/>148<space/></arg><arg name="issue"><space/>1<space/></arg><arg name="pages"><space/>42–4<space/></arg><arg name="year"><space/>2009<space/></arg><arg name="pmid"><space/>19902093<space/></arg><arg name="doi"><space/>10.1007/s10517-009-0624-x<space/></arg></template></extension><space/>It has yet to find clinical use outside of Russia.</paragraph><heading level='4'>Selank</heading><paragraph><link><target>Selank</target></link><space/>is an anxiolytic peptide based drug developed by the Institute of Molecular Genetics of the Russian academy of sciences. Selank is a heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It is a synthetic<space/><link><target>structural analog</target><part>analog</part></link><space/>of a human tetrapeptide<space/><link><target>tuftsin</target></link>. As such, it mimics many of its effects. It has been shown to modulate the expression of<space/><link><target>interleukin-6</target></link><space/>(IL-6) and affect the balance of T helper cell cytokines. There is evidence that it may also modulate the expression of<space/><link><target>brain-derived neurotropic factor</target></link><space/>in rats.<template><target>mcn</target><arg name="date">October 2015</arg></template></paragraph><heading level='4'>Bromantane</heading><paragraph><link><target>Bromantane</target></link><space/>is a stimulant drug with anxiolytic properties developed in Russia during the late 1980s, which acts mainly by inhibiting the reuptake of both dopamine and serotonin in the brain, although it also has anticholinergic effects at very high doses. Study results suggest that the combination of psychostimulant and anxiolytic actions in the spectrum of psychotropic activity of bromantane is effective in treating asthenic disorders compared to placebo.</paragraph><heading level='4'>Emoxypine</heading><paragraph><link><target>Emoxypine</target></link><space/>is an<space/><link><target>antioxidant</target></link><space/>that is also an anxiolytic. Its chemical structure resembles that of<space/><link><target>pyridoxine</target></link>, a type of vitamin B<xhtml:sub>6</xhtml:sub>.</paragraph><heading level='4'>Azapirones</heading><paragraph>Azapirones are a class of<space/><link><target>5-HT1A receptor</target><part>5-HT<xhtml:sub>1A</xhtml:sub><space/>receptor</part></link><space/><link><target>agonist</target><trail>s</trail></link>. Currently approved azapirones include<space/><link><target>buspirone</target></link><space/>(Buspar) and<space/><link><target>tandospirone</target></link><space/>(Sediel).</paragraph><heading level='4'>Hydroxyzine</heading><paragraph><link><target>Hydroxyzine</target></link><space/>(Atarax) is an old<space/><link><target>antihistamine</target></link><space/>originally approved for clinical use by the FDA in 1956. It possesses anxiolytic properties in addition to its antihistamine properties and is also licensed for the treatment of anxiety and tension. It is also used for its sedative properties as a premed before anesthesia or to induce sedation after anesthesia.<extension extension_name='ref'><template><target>cite web</target><arg name="url"><space/>http://www.medicinenet.com/hydroxyzine/article.htm</arg><arg name="title"><space/>hydroxyzine (Vistaril, Atarax)</arg><arg name="accessdate"><space/>17 May 2008</arg><arg name="author"><space/>medicine net</arg><arg name="publisher"><space/>medicinenet.com</arg><arg name="archiveurl"><space/>http://web.archive.org/web/20080513104646/http://www.medicinenet.com/hydroxyzine/article.htm</arg><arg name="archivedate"><space/>13 May 2008<space/></arg><arg name="deadurl"><space/>no</arg></template></extension><space/>It has been shown to be as effective as<space/><link><target>benzodiazepines</target></link><space/>in the treatment of<space/><link><target>generalized anxiety disorder</target></link>, while producing fewer side-effects.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Llorca PM, Spadone C, Sol O<space/></arg><arg name="title">Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study<space/></arg><arg name="journal">J Clin Psychiatry<space/></arg><arg name="volume">63<space/></arg><arg name="issue">11<space/></arg><arg name="pages">1020–7<space/></arg><arg name="date">November 2002<space/></arg><arg name="pmid">12444816<space/></arg><arg name="doi">10.4088/JCP.v63n1112</arg></template></extension></paragraph><heading level='4'>Pregabalin</heading><paragraph><link><target>Pregabalin</target></link>'s therapeutic effect appears after 1 week of use and is similar in effectiveness to<space/><link><target>lorazepam</target></link>,<space/><link><target>alprazolam</target></link>, and<space/><link><target>venlafaxine</target></link>, but pregabalin has demonstrated superiority by producing more consistent therapeutic effects for psychic and somatic anxiety symptoms. Long-term trials have shown continued effectiveness without the development of<space/><link><target>drug tolerance</target><part>tolerance</part></link>, and, in addition, unlike benzodiazepines, it does not disrupt<space/><link><target>sleep architecture</target></link><space/>and produces less severe cognitive and psychomotor impairment; it also has a low potential for abuse and dependence and may be preferred over the benzodiazepines for these reasons.<extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Bandelow<space/></arg><arg name="first1"><space/>B.<space/></arg><arg name="last2"><space/>Wedekind<space/></arg><arg name="first2"><space/>D.<space/></arg><arg name="last3"><space/>Leon<space/></arg><arg name="first3"><space/>T.<space/></arg><arg name="title"><space/>Pregabalin for the treatment of generalized anxiety disorder: a novel pharmacologic intervention<space/></arg><arg name="journal"><space/>Expert Rev Neurother<space/></arg><arg name="volume"><space/>7<space/></arg><arg name="issue"><space/>7<space/></arg><arg name="pages"><space/>769–81<space/></arg><arg name="date">Jul 2007<space/></arg><arg name="doi"><space/>10.1586/14737175.7.7.769<space/></arg><arg name="pmid"><space/>17610384<space/></arg></template></extension><extension extension_name='ref'><template><target>Cite journal</target><arg name="last1"><space/>Owen<space/></arg><arg name="first1"><space/>RT.<space/></arg><arg name="title"><space/>Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety<space/></arg><arg name="journal"><space/>Drugs Today (Barc)<space/></arg><arg name="volume"><space/>43<space/></arg><arg name="issue"><space/>9<space/></arg><arg name="pages"><space/>601–10<space/></arg><arg name="date">Sep 2007<space/></arg><arg name="doi"><space/>10.1358/dot.2007.43.9.1133188<space/></arg><arg name="pmid"><space/>17940637<space/></arg></template></extension></paragraph><heading level='4'>Menthyl isovalerate</heading><paragraph><link><target>Menthyl isovalerate</target></link><space/>is a flavoring food additive which is marketed as a sedative and anxiolytic drug in Russia under the name<space/><italics>Validol</italics>. Sublingual administration of<space/><italics>Validol</italics><space/>produces a sedative effect, and has moderate reflex and vascular dilative action caused by stimulation of sensory nerve receptors of the oral mucosa followed by the release of endorphins.<space/><italics>Validol</italics><space/>is typically administered<space/><italics>as needed</italics><space/>for symptom relief.<extension extension_name='ref'>The Great Soviet Encyclopedia http://encyclopedia2.thefreedictionary.com/Validol<template><target>full</target><arg name="date">November 2014</arg></template></extension><extension extension_name='ref'>Farmak Product Information - Validol http://farmak.ua/assets_images/drugs/instruction/en/25/Validol_Product_Information.pdf<template><target>full</target><arg name="date">November 2014</arg></template></extension><extension extension_name='ref'>Itop Doctor http://doctor.itop.net/DirectoryItem.aspx?DirId=1&amp;ItemId=268<template><target>full</target><arg name="date">November 2014</arg></template></extension></paragraph><heading level='4'>Cannabidiol</heading><paragraph>Cannabidiol (CBD) is a cannabinoid produced by<space/><italics><link><target>Cannabis sativa</target></link></italics><space/>and<space/><italics><link><target>Cannabis indica</target></link></italics>, and in marginal quantities by<space/><italics><link><target>Cannabis ruderalis</target></link></italics>. It is available in the<space/><link><target>United States</target></link><space/>in states where cannabis has been legalized for medical and general use. No<space/><link><target>lethal dose</target></link><space/>(or LD50) has been established from cannabidiol. In feral strains of cannabis, cannabidiol is produced in large quantities alongside the psychoactive cannabinoid<space/><link><target>THC</target><part>tetrahydrocannabinol</part></link>. Special strains of cannabis have been bred to yield high amounts of cannabidiol with significantly lowered synthesis of THC. Specific formulations for anxiety with a CBD to THC ratio of 18:1 are available in the US markets.</paragraph><heading level='4'>Tetrahydrocannabinol</heading><paragraph><link><target>THC</target><part>Tetrahydrocannabinol</part></link><space/>appears to be capable of both, having anxiolytic effect(s) and having anxiogenic effect(s).</paragraph><heading level='4'>Racetams</heading><paragraph>Some<space/><link><target>racetam</target></link><space/>based drugs such as<space/><link><target>aniracetam</target></link><space/>can have an antianxiety effect.<extension extension_name='ref'><template><target>cite journal</target><arg name="author">Malykh AG<space/></arg><arg name="author2">Sadaie MR<space/></arg><arg name="title">Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.<space/></arg><arg name="journal">Drugs.<space/></arg><arg name="volume">70<space/></arg><arg name="issue">3<space/></arg><arg name="pages">287–312<space/></arg><arg name="date">Feb 2010<space/></arg><arg name="pmid">20166767<space/></arg><arg name="doi">10.2165/11319230-000000000-00000</arg></template></extension></paragraph><heading level='3'>Herbal treatments</heading><paragraph>Certain natural substances are reputed to have anxiolytic properties, including the following:</paragraph><list type='bullet'><listitem><italics><link><target>Garcinia indica</target></link></italics><space/>(Kokum)<extension extension_name='ref'><template><target>cite journal</target><arg name="first1">Manish<space/></arg><arg name="last1">Patel<space/></arg><arg name="first2">Bhavesh<space/></arg><arg name="last2">Antala<space/></arg><arg name="first3">Chandana<space/></arg><arg name="last3">Barua<space/></arg><arg name="first4">Mangala<space/></arg><arg name="last4">Lahkar<space/></arg><arg name="year">2013<space/></arg><arg name="title">Anxiolytic activity of aqueous extract of ''Garcinia indica'' in mice<space/></arg><arg name="journal">International Journal of Green Pharmacy<space/></arg><arg name="volume">7<space/></arg><arg name="issue">4<space/></arg><arg name="pages">332–35<space/></arg><arg name="url">http://www.greenpharmacy.info/text.asp?2013/7/4/332/122089<space/></arg><arg name="doi">10.4103/0973-8258.122089</arg></template></extension></listitem><listitem><italics><link><target>Scutellaria lateriflora</target></link></italics><extension extension_name='ref'><template><target>cite journal</target><arg name="pmid">12652886</arg><arg name="year">2003</arg><arg name="last1">Wolfson</arg><arg name="first1">P</arg><arg name="last2">Hoffmann</arg><arg name="first2">DL</arg><arg name="title">An investigation into the efficacy of Scutellaria lateriflora in healthy volunteers</arg><arg name="volume">9</arg><arg name="issue">2</arg><arg name="pages">74–8</arg><arg name="journal">Alternative therapies in health and medicine</arg></template></extension></listitem><listitem><italics><link><target>Coriandrum sativum</target></link></italics><space/>(Coriander)<extension extension_name='ref'><template><target>cite journal</target><arg name="title">Coriandrum sativum: evaluation of its anxiolytic effect in the elevated plus-maze</arg><arg name="author">Emamghoreishi M, Khasaki M, Aazam MF</arg><arg name="year">2005</arg><arg name="journal">Journal of Ethnopharmacology</arg><arg name="volume">96</arg><arg name="issue">3</arg><arg name="pages">365–370</arg><arg name="doi">10.1016/j.jep.2004.06.022</arg><arg name="pmid">15619553</arg></template></extension></listitem><listitem><italics><link><target>Salvia elegans</target></link></italics><space/>(Pineapple Sage)<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1016/j.jep.2006.02.003<space/></arg><arg name="title">Antidepressant and anxiolytic effects of hydroalcoholic extract from Salvia elegans<space/></arg><arg name="year">2006<space/></arg><arg name="last1">Herrera-Ruiz<space/></arg><arg name="first1">Maribel<space/></arg><arg name="last2">García-Beltrán<space/></arg><arg name="first2">Yolanda<space/></arg><arg name="last3">Mora<space/></arg><arg name="first3">Sergio<space/></arg><arg name="last4">Díaz-Véliz<space/></arg><arg name="first4">Gabriela<space/></arg><arg name="last5">Viana<space/></arg><arg name="first5">Glauce S.B.<space/></arg><arg name="last6">Tortoriello<space/></arg><arg name="first6">Jaime<space/></arg><arg name="last7">Ramírez<space/></arg><arg name="first7">Guillermo<space/></arg><arg name="journal">Journal of Ethnopharmacology<space/></arg><arg name="volume">107<space/></arg><arg name="pages">53–8<space/></arg><arg name="pmid">16530995<space/></arg><arg name="issue">1</arg></template></extension></listitem><listitem><italics><link><target>Cannabidiol</target></link></italics><space/>(a<space/><link><target>cannabinoid</target></link><space/>found in<space/><link><target>Cannabis (drug)</target><part>marijuana</part></link>)<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1590/S0100-879X2006000400001<space/></arg><arg name="title">Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug<space/></arg><arg name="year">2006<space/></arg><arg name="last1">Zuardi<space/></arg><arg name="first1">A.W.<space/></arg><arg name="last2">Crippa<space/></arg><arg name="first2">J.A.S.<space/></arg><arg name="last3">Hallak<space/></arg><arg name="first3">J.E.C.<space/></arg><arg name="last4">Moreira<space/></arg><arg name="first4">F.A.<space/></arg><arg name="last5">Guimarães<space/></arg><arg name="first5">F.S.<space/></arg><arg name="journal">Brazilian Journal of Medical and Biological Research<space/></arg><arg name="volume">39<space/></arg><arg name="issue">4<space/></arg><arg name="pages">421–9<space/></arg><arg name="pmid">16612464</arg></template></extension></listitem></list><heading level='3'>Supplements and over-the-counter pharmaceutical drugs</heading><paragraph><link><target>Picamilon</target></link><space/>is a<space/><link><target>prodrug</target></link><space/>formed by combining<space/><link><target>niacin</target></link><space/>with<space/><link><target>GABA</target></link><space/>that is able to cross the bloodbrain barrier and is then hydrolyzed into GABA and niacin. It is theorized that the GABA released in this process activates<space/><link><target>GABA receptors</target></link>, with potential to produce an anxiolytic response.<extension extension_name='ref' name="pmid2884549"><template><target>cite journal</target><arg name="author"><space/>Shephard RA
</arg><arg name="title"><space/>Behavioral effects of GABA agonists in relation to anxiety and benzodiazepine action
</arg><arg name="journal"><space/>Life Sci.
</arg><arg name="volume"><space/>40
</arg><arg name="issue"><space/>25
</arg><arg name="pages"><space/>2429–36
</arg><arg name="date">June 1987
</arg><arg name="pmid"><space/>2884549
</arg><arg name="doi"><space/>10.1016/0024-3205(87)90758-2
</arg></template></extension><extension extension_name='ref' name="pmid16377242"><template><target>cite journal</target><arg name="author"><space/>Foster AC, Kemp JA
</arg><arg name="title"><space/>Glutamate- and GABA-based CNS therapeutics
</arg><arg name="journal"><space/>Curr Opin Pharmacol
</arg><arg name="volume"><space/>6<space/></arg><arg name="issue"><space/>1
</arg><arg name="pages"><space/>7–17
</arg><arg name="date">February 2006
</arg><arg name="pmid"><space/>16377242
</arg><arg name="doi"><space/>10.1016/j.coph.2005.11.005
</arg></template></extension>Picamilon is sold in the United States as a dietary supplement, while in Russia it is sold as a prescription drug.</paragraph><paragraph><link><target>Chlorpheniramine</target></link><space/>(Chlor-Trimeton)<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1007/s00213-009-1695-0<space/></arg><arg name="title">Chlorpheniramine exerts anxiolytic-like effects and activates prefrontal 5-HT systems in mice<space/></arg><arg name="year">2009<space/></arg><arg name="last1">Miyata<space/></arg><arg name="first1">Shigeo<space/></arg><arg name="last2">Hirano<space/></arg><arg name="first2">Shoko<space/></arg><arg name="last3">Ohsawa<space/></arg><arg name="first3">Masahiro<space/></arg><arg name="last4">Kamei<space/></arg><arg name="first4">Junzo<space/></arg><arg name="journal">Psychopharmacology<space/></arg><arg name="volume">213<space/></arg><arg name="issue">2–3<space/></arg><arg name="pages">441–52<space/></arg><arg name="pmid">19823805</arg></template></extension><space/>and<space/><link><target>diphenhydramine</target></link><space/>(Benadryl) have<space/><link><target>hypnotic</target></link><space/>and<space/><link><target>sedative</target></link><space/>effects with mild anxiolytic-like properties (<link><target>off-label use</target></link>). These drugs are approved by the FDA for<space/><link><target>allergy</target><part>allergies</part></link>,<space/><link><target>rhinitis</target></link>, and<space/><link><target>urticaria</target></link>.</paragraph><paragraph><link><target>Melatonin</target></link><space/>has anxiolytic properties, likely mediated by the<space/><link><target>benzodiazepine</target></link>/<link><target>GABAergic</target></link><space/>system.<extension extension_name='ref'><template><target>cite journal</target><arg name="pmid">7905658<space/></arg><arg name="year">1993<space/></arg><arg name="last1">Pierrefiche<space/></arg><arg name="first1">G<space/></arg><arg name="last2">Zerbib<space/></arg><arg name="first2">R<space/></arg><arg name="last3">Laborit<space/></arg><arg name="first3">H<space/></arg><arg name="title">Anxiolytic activity of melatonin in mice: Involvement of benzodiazepine receptors<space/></arg><arg name="volume">82<space/></arg><arg name="issue">2<space/></arg><arg name="pages">131–42<space/></arg><arg name="journal">Research communications in chemical pathology and pharmacology</arg></template></extension><space/>It has been used experimentally as an effective premedicant for general anesthesia in surgical procedures.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1111/j.1600-079X.2006.00384.x<space/></arg><arg name="title">Melatonin and anesthesia: A clinical perspective<space/></arg><arg name="year">2007<space/></arg><arg name="last1">Naguib<space/></arg><arg name="first1">Mohamed<space/></arg><arg name="last2">Gottumukkala<space/></arg><arg name="first2">Vijaya<space/></arg><arg name="last3">Goldstein<space/></arg><arg name="first3">Peter A.<space/></arg><arg name="journal">Journal of Pineal Research<space/></arg><arg name="volume">42<space/></arg><arg name="pages">12–21<space/></arg><arg name="pmid">17198534<space/></arg><arg name="issue">1</arg></template></extension></paragraph><paragraph><link><target>Inositol</target></link>:<extension extension_name='ref'><template><target>cite journal</target><arg name="author"><space/>Fux M, Levine J, Aviv A, Belmaker RH
</arg><arg name="title"><space/>Inositol treatment of obsessive-compulsive disorder
</arg><arg name="journal"><space/>American Journal of Psychiatry
</arg><arg name="year"><space/>1996
</arg><arg name="volume"><space/>153
</arg><arg name="issue"><space/>9
</arg><arg name="pages"><space/>1219–1221
</arg><arg name="pmid">8780431<space/></arg></template></extension><space/>In a double-blind, controlled trial,<space/><italics>myo</italics>-inositol (18&amp;nbsp;grams daily) was superior to<space/><link><target>fluvoxamine</target></link><space/>for decreasing the number of panic attacks and had fewer<space/><link><target>adverse effect</target><part>side-effect</part><trail>s</trail></link>.<extension extension_name='ref' name="Palatnik"><template><target>cite journal</target><arg name="author"><space/>Palatnik A, Frolov K, Fux M, Benjamin J
</arg><arg name="title"><space/>Double-blind, controlled, crossover trial of inositol versus fluvoxamine for the treatment of panic disorder
</arg><arg name="journal"><space/>Journal of Clinical Psychopharmacology
</arg><arg name="year"><space/>2001
</arg><arg name="volume"><space/>21
</arg><arg name="issue"><space/>3
</arg><arg name="pages"><space/>335–339
</arg><arg name="pmid">11386498<space/></arg><arg name="doi"><space/>10.1097/00004714-200106000-00014
</arg></template></extension></paragraph><heading level='3'>Future drugs</heading><paragraph>Due to deficits with existing anxiolytics (either in terms of efficacy or side-effect profile), research into novel anxiolytics is active. Possible candidates for future drugs include:</paragraph><list type='bullet'><listitem><link><target>BNC210</target></link></listitem><listitem><link><target>CL-218,872</target></link></listitem><listitem><link><target>L-838,417</target></link></listitem><listitem><link><target>SL-651,498</target></link></listitem><listitem><link><target>S32212</target></link></listitem><listitem><link><target>PH94B</target></link></listitem></list><heading level='3'>Common drugs</heading><paragraph>Prescription-free drugs are often poor anxiolytics and often worsen the symptoms over time<template><target>Citation needed</target><arg name="date">April 2013</arg></template>. However, they are often used for self-medication because of their wide availability (e.g.<space/><link><target>alcoholic beverages</target></link>).</paragraph><heading level='4'>Alcohol</heading><paragraph><template><target>See also</target><arg>Short-term effects of alcohol</arg></template></paragraph><paragraph>Ethanol is used as an anxiolytic, sometimes by<space/><link><target>self-medication</target></link>.<space/><link><target>fMRI</target></link><space/>can measure the anxiolytic effects of alcohol in the human brain.<extension extension_name='ref'><template><target>cite journal</target><arg name="doi">10.1523/JNEUROSCI.0086-08.2008<space/></arg><arg name="title">Why We Like to Drink: A Functional Magnetic Resonance Imaging Study of the Rewarding and Anxiolytic Effects of Alcohol<space/></arg><arg name="year">2008<space/></arg><arg name="last1">Gilman<space/></arg><arg name="first1">J. M.<space/></arg><arg name="last2">Ramchandani<space/></arg><arg name="first2">V. A.<space/></arg><arg name="last3">Davis<space/></arg><arg name="first3">M. B.<space/></arg><arg name="last4">Bjork<space/></arg><arg name="first4">J. M.<space/></arg><arg name="last5">Hommer<space/></arg><arg name="first5">D. W.<space/></arg><arg name="journal">Journal of Neuroscience<space/></arg><arg name="volume">28<space/></arg><arg name="issue">18<space/></arg><arg name="pages">4583–91<space/></arg><arg name="pmid">18448634<space/></arg><arg name="pmc">2730732</arg></template></extension><space/>The<space/><link><target>British National Formulary</target></link><space/>states, &quot;Alcohol is a poor hypnotic because its<space/><link><target>diuretic</target></link><space/>action interferes with<space/><link><target>sleep</target></link><space/>during the latter part of the night.&quot; Alcohol is also known to induce alcohol-related<space/><link><target>sleep disorder</target><trail>s</trail></link>.<extension extension_name='ref'>http://pubs.niaaa.nih.gov/publications/aa41.htm<template><target>full</target><arg name="date">November 2014</arg></template></extension></paragraph><heading level='4'>Inhalants</heading><paragraph><template><target>see also</target><arg>Inhalant abuse#Patterns of non-medical usage</arg><arg>Street children in Latin America#Drugs</arg></template></paragraph><paragraph>The anxiolytic effects of solvents act as positive modulators of GABAA receptors (Bowen and colleagues 2006).<extension extension_name='ref'><template><target>cite journal</target><arg name="first1">Matthew O.<space/></arg><arg name="last1">Howard<space/></arg><arg name="first2">Scott E.<space/></arg><arg name="last2">Bowen<space/></arg><arg name="first3">Eric L.<space/></arg><arg name="last3">Garland<space/></arg><arg name="first4">Brian E.<space/></arg><arg name="last4">Perron<space/></arg><arg name="first5">Michael G.<space/></arg><arg name="last5">Vaughn<space/></arg><arg name="pmid">22003419<space/></arg><arg name="year">2011<space/></arg><arg name="title">Inhalant use and inhalant use disorders in the United States<space/></arg><arg name="volume">6<space/></arg><arg name="issue">1<space/></arg><arg name="pages">18–31<space/></arg><arg name="pmc">3188822<space/></arg><arg name="journal">Addiction science & clinical practice</arg></template></extension></paragraph><heading level='2'>See also</heading><list type='bullet'><listitem><link><target>ATC code N05#N05B Anxiolytics</target></link></listitem></list><heading level='2'>References</heading><paragraph><template><target>Reflist</target><arg>2</arg></template></paragraph><paragraph><template><target>Major Drug Groups</target></template><template><target>Anxiolytics</target></template></paragraph><paragraph><link><target>Category:Anxiolytics</target><part></part></link><link><target>Category:Anxiety disorder treatment</target></link></paragraph></article>